Loading…
Loading…
Announcements from Anixa Biosciences, published the moment they cross the wire. Get them by email.
2024
Mar 11, 2024
8:00 AM EDT
Dr. Amit Kumar , Chairman and CEO of Anixa, will participate in the 24 th Annual World Vaccine Congress being held April 1-4, 2024 . Dr. Kumar will speak on Thursday, April 4 th , in the Cancer Immunotherapy Track.
Feb 12, 2024
7:30 AM EST
Treatment has commenced for the fourth patient in the ongoing Phase 1 clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer. The study is being conducted through a research partnership with Moffitt Cancer Center.
Jan 29, 2024
8:50 AM EST
Its participation in the 2024 NeauxCancer Conference organized by the Cancer Advocacy Group of Louisiana (CAGLA), being held February 29 – March 2, 2024 in New Orleans . Anixa Chairman and CEO Dr. Amit Kumar will present and meet one-on-one with investors throughout the day on Friday, March 1 st .
Jan 23, 2024
7:55 AM EST
Its collaborator, Cleveland Clinic, has received a "Decision to Grant" notice from the Japan Patent Office (JPO) for the patent application titled "Ovarian Cancer Vaccines."
Jan 10, 2024
9:00 AM EST
It will present an overview of its business and clinical programs at the Sidoti Micro-Cap Virtual Conference, taking place January 17-18, 2024 . Anixa Chairman and CEO Dr. Amit Kumar will present on Wednesday, January 17, 2024 , at 12:15 PM ET .
2023
Dec 14, 2023
7:15 AM EST
It will present an overview of its business and provide updates on its clinical programs at Biotech Showcase, taking place January 8-10, 2024 in San Francisco, California in parallel to the 42 nd Annual J.P. Morgan Healthcare Conference ("JPM Week 2024").
Dec 06, 2023
6:00 PM EST
New and updated positive results from the Phase 1 clinical trial of its breast cancer vaccine. The trial is being conducted in collaboration with Cleveland Clinic with funding by a grant from the U.S. Department of Defense.
Dec 06, 2023
4:05 PM EST
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX ), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, will publicly release new data this evening from the ongoing Phase 1 clinical trial of its breast cancer vaccine, which was presented for the first time today at…
Nov 27, 2023
8:30 AM EST
Its partner, Cleveland Clinic, has received an "Intention to Grant" notice from the European Patent Office ("EPO") for the patent application titled "Ovarian Cancer Vaccines."
Oct 31, 2023
8:30 AM EDT
It will present at the Ovarian Cancer National Conference taking place from November 1 – 3, 2023.
Oct 23, 2023
8:30 AM EDT
It has appointed Mark A. Goldberg , MD, to its Cancer Business Advisory Board (CBAB).
Oct 13, 2023
8:30 AM EDT
That, in partnership with Moffitt Cancer Center, it has completed treatment of the first patient cohort in the ongoing clinical trial of Anixa's novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.
Oct 03, 2023
8:30 AM EDT
The U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent Number 11,786,489, which broadens protection of Anixa's novel ovarian cancer vaccine technology.
Sep 19, 2023
8:30 AM EDT
It has established a Cancer Business Advisory Board (CBAB), whose purpose is to provide guidance on the Company's clinical and business development initiatives. The CBAB will be co-chaired by Anixa Chairman and CEO, Dr. Amit Kumar , and Board Director, Dr. Arnold Baskies , and will include the following members:
Aug 31, 2023
8:30 AM EDT
Management will participate in two investor conferences in September.
Aug 28, 2023
8:30 AM EDT
That, in partnership with Moffitt Cancer Center, it has commenced treatment of the third patient in the ongoing clinical trial of Anixa's novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.
Aug 14, 2023
8:30 AM EDT
Dr. Pamela D. Garzone , Anixa's Chief Development Officer, has been invited to present at the 8 th Annual CAR-TCR Summit being held from August 29 – September 1, 2023 in Boston, MA.
Aug 07, 2023
8:30 AM EDT
Its partner, Cleveland Clinic, has begun enrolling subjects in a treatment arm evaluating the combination of the Company's breast cancer vaccine with Keytruda® (pembrolizumab).
Jul 27, 2023
8:30 AM EDT
The U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance broadening protection of Anixa's novel ovarian cancer vaccine technology, which has been exclusively licensed from, and is being developed in partnership with, Cleveland Clinic.
Jul 11, 2023
8:30 AM EDT
The Canadian Intellectual Property Office has issued Canadian Patent 2,989,807 covering Anixa's novel Chimeric Antigen Receptor-T cell (CAR-T) cancer treatment technology, which has been licensed from The Wistar Institute and is being developed in partnership with Moffitt Cancer Center.
